About Eddingpharm
Eddingpharm is a Healthcare company based in Shanghai (China) founded in 2001. Provider of biopharmaceutical products for critical illnesses. Eddingpharm has raised $56 million across 2 funding rounds from investors including Orbimed, Taikang Fund and H&Q Asia Pacific. Eddingpharm has completed 1 acquisition, including ACT Biotech. Eddingpharm offers products and services including Anti-Infection Drugs and Cardiovascular Therapies. Its focus areas include Traditional Pharmaceuticals, Generics and Therapeutic Areas.
Company details
Eddingpharm was founded in 2001 and is headquartered in Shanghai, China. Operations in the biopharmaceutical sector are centered on critical illnesses with unmet needs. Global technologies and products are introduced via licensing and acquisitions, encompassing clinical trials, manufacturing, and sales. Production facilities are maintained to international standards, while research and development efforts target new pharmaceuticals. Commercial activities are guided by data analysis and compliance protocols.
- Headquarters Shanghai, China
- SectorsHealthcare
- Website eddingpharm.com
- Social LinkedIn
- Legal Name Eddingpharm
- Total Equity Funding$56M (USD)
in 2 rounds
- Latest Funding Round$32M (USD), Series B
Nov 2017
- InvestorsOrbimed
& 4 more
- Investments & Acquisitions
Products & Services of Eddingpharm
Eddingpharm offers a comprehensive portfolio of products and services, including Anti-Infection Drugs and Cardiovascular Therapies.
Drugs for anti-infection treatments are developed and distributed to address clinical demands in China
Therapies for cardiovascular diseases are provided through global partnerships and local commercialization efforts
Funding Insights of Eddingpharm
Eddingpharm has successfully raised a total of $56M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $32 million completed in November 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $56M
- Total Rounds 2
- Last Round Series B — $32M
- First Round $24M
(Oct 2010)
- Investors Count 5
All 2 funding rounds of Eddingpharm with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2017 | $32M | Series B | – | Taikang Asset Management | |
| Oct 2010 | $24M | Series B | – | Orbimed, Domain Associates |
5 investors in total: 5 institutional.
Investors in Eddingpharm
Eddingpharm has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Orbimed, Taikang Fund and H&Q Asia Pacific.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Buyouts are targeted via private equity by H&Q Asia Pacific. | hqap.com | Palo Alto, United States | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Life science & tech focused VC firm investing in the US | domainvc.com | Princeton, United States | ||
Taikang Fund is engaged in fund management and investment services. | tkfunds.com.cn | China | ||
Venture capital firm focused on early-stage investments | sequoiacap.cn | Beijing, China |
Investor details for Eddingpharm
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Eddingpharm
Eddingpharm has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include ACT Biotech.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Small molecule kinase inhibitors for cancer therapy are developed. | actbiotech.com | San Francisco, United States | 2008 | Jan 2014 | $95M |
Complete acquisition details for Eddingpharm
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Eddingpharm
4 dated milestones of Eddingpharm across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Eddingpharm is founded.
- Funding First funding round of $24.0M.
- Acquisition Acquires ACT Biotech.
- Funding Latest funding round, Series B, of $32.0M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Eddingpharm
Eddingpharm was founded in 2001 and raised its 1st funding round 9 years after it was founded.
Eddingpharm is headquartered in Shanghai, China.
Eddingpharm is a funded company, having raised a total of $56M across 2 funding rounds to date. The company's 1st funding round was a Series B of $24M, raised on Oct 2010.
Eddingpharm was founded in 2001 and is headquartered in Shanghai, China. Operations in the biopharmaceutical sector are centered on critical illnesses with unmet needs. Global technologies and products are introduced via licensing and acquisitions, encompassing clinical trials, manufacturing, and sales. Production facilities are maintained to international standards, while research and development efforts target new pharmaceuticals. Commercial activities are guided by data analysis and compliance protocols.
Eddingpharm offers Anti-Infection Drugs and Cardiovascular Therapies.
Eddingpharm has made 1 acquisition, including ACT Biotech.
Eddingpharm has 5 investors. Key investors include Orbimed, Taikang Fund, H&Q Asia Pacific, Sequoia Capital, and Domain Associates.
Eddingpharm operates through Eddingpharm.